<DOC>
	<DOCNO>NCT00943228</DOCNO>
	<brief_summary>The primary objective study determine whether 4 gram daily mycophenolate mofetil ( MMF ) result great proportion individual adequately expose measure drug level ( area curve &gt; 40 mg*hr/L ) .</brief_summary>
	<brief_title>Intensified Dosing Cellcept ( Mycophenolate Mofetil ) Kidney Transplantation</brief_title>
	<detailed_description>Several study show early exposure adequate level immunosuppression require reduce acute rejection rate kidney transplantation . ( 1 , 2 ) Our center show early exposure mycophenolate mofetil ( MMF Cellcept ) associate acute rejection rate many patient underexpose early transplant period . ( 2 ) In recently complete multicenter Canadian ( CLEAR ) study find high dos mycophenolate mofetil ( MMF 3 gram daily versus 2 gram daily ) associate good early exposure day 5 associate less rejection increase toxicity . ( 3 ) The best cut point discriminate low high rejection rate mycophenolic acid ( MPA ) 12 hour area curve ( AUC ) 40 mg*hr/L . Patients level experienced rejection rate 50 % compare &lt; 16 % level . Even high dose 26 % subject inadequately expose . Since medication adjustment base drug level hamper steady state condition turn around time MPA test interested explore even high initial dos MMF aim maximize number patient achieve adequate early exposure MPA . Objectives : The primary objective study determine whether 4 gms daily MMF result great proportion individual adequately expose measure day 5 MPA AUC &gt; 40 mg*hr/L . The secondary objective study assess ability strategy achieve target MPA AUC exposure 40-60 mg*hr/L day 14 determine distribution MMF dose necessary achieve level exposure . Safety data ( hemoglobin WBC count , need dose change base gastrointestinal intolerance , acute rejection , renal function , wound infection ) also collect first 3 month post transplantation .</detailed_description>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Patients undergo single organ kidney transplantation . Age &gt; 18 year old . Patients would normally receive standard therapy basiliximab , tacrolimus , MMF steroid . All patient require sign inform consent . Patients exclude require antithymocyte induction therapy , document gastroparesis , know intolerance MMF , prescribe cyclosporine . As standard policy woman childbearing age inform risk immunosuppressive drug fetal outcomes require use 2 form birth control .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Renal transplantation</keyword>
	<keyword>Adequate exposure</keyword>
	<keyword>Acute rejection</keyword>
	<keyword>mycophenolate mofetil</keyword>
	<keyword>immunosuppression</keyword>
</DOC>